Mgi GP, Inc.
Records under this name other than the patents Mgi GP, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,236,802 | PARP inhibitor compounds, compositions and methods of use Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,268,138 | Compounds, methods and pharmaceutical compositions for inhibiting PARP Formerly held Term ended Term ended Jun 15, 2025 · From the USPTO record | Term ended | Term ended Jun 15, 2025 | From the USPTO record |
| US 7,456,178 | Compounds, methods and pharmaceutical compositions for inhibiting PARP Term ended Term ended May 26, 2024 · From the USPTO record | Term ended | Term ended May 26, 2024 | From the USPTO record |
| US 6,770,660 | Method for Inhibiting Platelet Aggregation Formerly held Term ended Term ended May 1, 2023 · High confidence | Term ended | Term ended May 1, 2023 | High confidence |
| US 7,138,543 | Thiolalkyl benzoic acid derivatives Formerly held Term ended Term ended Oct 1, 2022 · From the USPTO record | Term ended | Term ended Oct 1, 2022 | From the USPTO record |
| US 6,740,777 | Thiolalkyl benzoic acid derivatives Formerly held Term ended Term ended May 30, 2022 · From the USPTO record | Term ended | Term ended May 30, 2022 | From the USPTO record |
| US 8,058,275 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP Formerly held Lapsed on the fee record Ended Nov 15, 2019 · From the USPTO record | Lapsed on the fee record | Ended Nov 15, 2019 | From the USPTO record |
| US 7,235,557 | Compounds and their uses Lapsed on the fee record Ended Jun 26, 2019 · From the USPTO record | Lapsed on the fee record | Ended Jun 26, 2019 | From the USPTO record |
| US 7,229,978 | Process for preparing water soluble phosphonooxymethyl derivatives of alcohol and phenol Formerly held Lapsed on the fee record Ended Jun 12, 2019 · From the USPTO record | Lapsed on the fee record | Ended Jun 12, 2019 | From the USPTO record |
| US 6,136,794 | Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist Formerly held Term ended Term ended Jan 29, 2019 · From the USPTO record | Term ended | Term ended Jan 29, 2019 | From the USPTO record |